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Background: Although its biological function remains poorly understood, REG4 is reported to be a potent activator
of the EGFR/Akt/AP-1 signaling pathway in colon cancer cells and closely linked with the inhibition of apoptosis.
Methods: SKOV3 cells were transfected with a REG4-expressing plasmid or treated with recombinant REG4. We then
analyzed proliferation, cell cycle, apoptosis, invasion and metastasis or expression of related molecules. REG4 expression
was examined in normal ovarian tissue, benign and borderline tumors, and cancers by immunohistochemistry or
real-time PCR.
Results: REG4 overexpression and the recombinant protein inhibited cell apoptosis, enhanced G2/S progression,
proliferation, migration and invasion. Furthermore, expression of Wnt5a, p70s6k, survivin and VEGF expression was
increased, while Bax expression was decreased at both the mRNA and protein levels compared to control or mock
cells (P < 0.05). REG4 mRNA levels were higher in benign tumors and primary cancer compared to those in normal
ovarian tissue (P < 0.05) while, REG4 protein expression was higher in all three tumor types than that in normal ovarian
tissue (P < 0.05). Higher REG4 mRNA expression was observed in mucinous carcinomas than serous carcinomas
(P < 0.05), and in well- and moderately-differentiated carcinomas than poorly-differentiated carcinomas (P < 0.05).
Survival analysis revealed an inverse relationship between REG4 expression and cumulative or relapse-free survival
rates of the patients with ovarian cancer as an independent factor (P < 0.05).
Conclusions: Our findings indicate that aberrant REG4 expression plays an essential role in early ovarian
carcinogenesis and is closely linked to mucinous ovarian tumors, differentiation and adverse prognosis of ovarian
cancer by modulating proliferation, apoptosis, migration and invasion.
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Ovarian cancer is one of the leading causes of death due
to cancer in women worldwide. The 5-year survival rate
for all stages of ovarian cancer is 35–38 %. Due to the
lack of effective methods for early diagnosis, most
ovarian cancers are only diagnosed at an advanced
stage. As such, it is a serious threat to women’s health.
Ovarian cancers are believed to originate in the ovarian
epithelium, with risk factors such as genetic mutations
and family history [1, 2]. An improved understanding of
the changes in gene expression and associated mole-
cular mechanisms during ovarian carcinogenesis, as
well as identification of novel biomarkers and targets* Correspondence: zheng_huachuan@hotmail.com
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unless otherwise stated.for diagnosis and treatment may result in improvements
in diagnosis, treatment and prevention of ovarian
cancer.
Regenerating (REG) protein is induced during regener-
ation of pancreatic islets and belongs to the calcium-
dependent lectin (C-type lectin) gene superfamily. It
encodes a group of small multifunctional secretory
proteins which function as acute phase reactants, lectins,
anti-apoptotic factors and growth agents, and include
growth factors for pancreatic β-cells, neural cells and
epithelial cells in the digestive system. These proteins are
primarily involved in cell proliferation and differentiation,
inflammation, diabetes and carcinogenesis. To date, three
subtypes of the REG gene have been identified in humans:
REG1 (1α and 1β); REG3 (III and HIP/PAP); and REG4
[3–5]. REG4, which is located on human chromosomehis is an Open Access article distributed under the terms of the Creative
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splicing [6], was identified by high-throughput sequencing
of a cDNA library from ulcerative colitis tissues, implying
that it has a central role in initiating the multi-step process
of colorectal carcinogenesis.
Studies in colon cancer cell lines showed that REG4
expression was enhanced by stimulation with transform-
ing growth factor (TGF)α, EGF, bFGF and HGF [7], and
in hepatocellular carcinoma cell lines by stimulation
with TGF-β [8]. Furthermore, REG4 has been reported
to be a potent activator of the epidermal growth factor
receptor/Akt kinase/activator protein-1 (EGFR/Akt/AP-1)
signaling pathway, leading to increased expression of
Bcl-2, Bcl-xl and survivin, which are associated with
apoptosis inhibition [9]. Treatment with recombinant
REG4 protein protected normal intestinal crypt cells from
ionizing radiation (IR)-induced apoptosis by increasing ex-
pression of Bcl-2, Bcl-xL and survivin; whereas overex-
pression of REG4 in human colorectal cancer (CRC) cells
was associated with increased resistance to IR-induced
apoptosis. REG4 has also been found to induce expression
of matrix metalloproteinase-7, which is involved in liver
metastasis [10]. Naito et al. [11] suggested that nuclear
CDX2 regulates REG4 transcription by binding to its 5′-
flanking region. Li et al. [12] reported that proteoglycan
from Phellinus linteus might suppress CRC cells by inhi-
biting the REG4/EGFR/Akt signaling pathway.
In our previous study, REG4 mRNA and protein expres-
sion levels were found to be increased in gastric intestinal
metaplasia compared to those in gastric cancer and nor-
mal mucosa; higher serum REG4 levels were observed in
patients with gastric cancer compared to healthy
individuals; and REG4 was expressed more frequently in
signet ring cell carcinoma, which closely correlated with
MUC-2, and MUC-5 AC expression [13]. Expression of
REG4 in CRC cells was significantly lower than in adjacent
non-neoplastic mucosa or adenoma, inversely correlated
with poor differentiation and venous invasion, and was
positively linked to MUC2 expression and EGFR phos-
phorylation at Tyr1068 [14]. Wang et al. [15] found that
expression of both REG4 mRNA and protein in glioma
tissues was significantly higher than that in corresponding
non-neoplastic brain tissues, and that increased expression
of REG4 was significantly associated with advanced
pathological grade and low Karnofsky performance
score of gliomas. Here, we investigated the effect of REG4
overexpression and recombinant REG4 on the proliferation,
apoptosis, invasion and migration of ovarian cancer cell
lines, and explored the related mechanisms. In addition, we
examined REG4 expression in normal ovarian tissue,
benign and borderline ovarian tumors, and primary and
metastatic cancers, and compared our findings with the
clinicopathological and prognostic parameters of tumors
surgically resected from the patients with ovarian cancer.Methods
Cell culture and transfection
Ovarian cancer cell lines: CAOV-3 (serous adenocarcin-
oma); OVCAR3 (serous cystadenocarcinoma); SKOV3
(papillary serous cystadenocarcinoma); HO8910 (serous
cystadenocarcinoma); HO8910-PM (invasive adenocarcin-
oma); and ES-2 (clear cell carcinoma) were purchased
from ATCC (Manassas, VA, USA), SKOV3/DDP (cis-
platin-resistant SKOV3) was purchased from the Tumor
Cell Bank of Chinese Academy of Medical Science (Pe-
king, China). H08910, H08910-PM, OVCAR3 and
SKOV3/DDP were maintained in RPMI 1640; CAOV3
was maintained in DMEM; ES-2 and SKOV3 were main-
tained in McCoy’s 5A, all mediums were supplemented
with 10 % fetal bovine serum (FBS), 100 U/mL penicillin
and 100 μg/mL streptomycin, in a humidified atmosphere
of 5 % CO2 at 37 °C. The cells were seeded in dishes 24 h
before transfection with pCI-REG4 (kindly donated by
Prof. Akira Sugawara; Department of Advanced Biological
Sciences for Regeneration, Tohoku University, Japan).
Cells were treated with recombinant REG4 (BioVendor,
Asheville, NC, USA), or transfected with pCI-REG4
(SKOV3/REG4) or pCI vector (Mock). Transfected cells
were selected using 500 mg/L G418 according
to the manufacturer’s instructions (QIAGEN, Valencia,
CA, USA).
Cell viability assay
Briefly, 2.0 × 103 cells/well was seeded on 96-well plates.
After cells were adhered at 37 °C in an atmosphere of
5 % CO2, 10 μL of CCK-8 (Cell Counting Kit-8; Dojindo,
Mashikimachi, Japan) solution was added to each well at
different time-points (0 h, 12 h, 24 h, and 48 h) and the
plates were incubated for a further 3 h. The number of
viable cells was counted by measuring the absorbance at
450 nm using a microplate reader.
Flow cytometric cell cycle analysis
After incubation at 37 °C in an atmosphere of 5 % CO2 for
48 h, cells were detached by trypsinization, collected,
washed twice with PBS and fixed in 5 mL ice-cold ethanol
for at least 2 h. The cells were again washed twice with PBS
and incubated with 500 μL RNase (0.25 mg/mL) for 30 min
at 37 °C. Cells were pelleted and resuspended in propidium
iodide (PI) at a concentration of 50 μg/mL and incubated
in the dark for 30 min at 4 °C. Cell cycle analysis was per-
formed by analyzing PI staining levels by flow cytometry.
Flow cytometric apoptosis assay
Cell apoptosis was determined by PI and Annexin V-FITC
staining (KeyGEN Biotech, Nanjing, China). In brief, cells
were incubated for 48 h, washed twice with ice-cold PBS,
resuspended at a density of 1 × 106 cells/mL in 1× Binding
Buffer and then incubated with 200 μL 1× Binding Buffer
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vortexed and incubated for 15 min at 25 °C in the dark,
then 300 μL 1× Binding Buffer and 5 μL PI was added to
each tube. Samples were gently vortexed and incubated
for a maximum of 1 h at 25 °C in the dark. Flow cytometry
was performed within 1 h of incubation.
Wound healing assay
Cells were seeded at a density of 1.0 × 106 cells/well in
6-well culture plates. After reaching confluence, each
cell monolayer was scraped with a 200 μL pipette tip to
create a scratch, washed three times with PBS, and cul-
tured in FBS-free medium. Cells were photographed at
0, 12, 24, and 48 h (n = 3) and the scratch area was mea-
sured using Image software (National Institutes of
Health, Bethesda, MD, USA). The wound healing rate
= (area of original wound-area of actual wound at differ-
ent times)/ area of original wound × 100 %.
Cell invasion assays
Cells (5 × 105) were seeded in the top chamber of
Matrigel-coated transwell plates (BD Bioscience, San Jose,
CA, USA) with serum-free McCoy’s 5A medium. The
lower compartment of the chamber contained 10 % v/v
FBS as a chemoattractant. After incubation for 48 h, cells
on the membrane were scrubbed, washed with PBS, fixed
in 100 % methanol and stained with Crystal violet dye to
measure invasion.
Selection of patient tissue samples
Samples of normal ovarian tissue, ovarian epithelial benign
tumors (serous cystadenoma and mucinous cystadenoma)
and borderline tumors, primary and metastatic cancers in
the omentum were collected from surgical resections be-
tween January 2003 and December 2011 at Department of
Gynecology, The First Affiliated Hospital of China Med-
ical University, Shenyang, China. The average age at sur-
gery was 51.2 years (range 20–81 years). The median age
(56 years) was chosen as the divider in Table 2 and Add-
itional file 1: Table S2. The majority of samples were rou-
tinely prepared for storage in pathological blocks; the
remaining samples were frozen immediately in liquid ni-
trogen and stored at −80 °C until required. In total, 123
samples were fresh-frozen for RT-PCR analysis, while 337
samples were fixed in paraffin for immunostaining analysis
(details can be found in Additional file 1: Table S1). Each
ovarian cancer was staged according to the International
Federation of Gynecology and Obstetrics (FIGO) staging
system and histology was defined according to World
Health Organization (WHO) classification system. Classi-
fication of the differentiation classes of the samples (HE
staining) was evaluated by experienced physiologists ac-
cording to the tumor cell differentiation grades. None of
the patients had undergone chemotherapy, radiotherapy oradjuvant treatment prior to surgery. Patients were followed
up by consulting their case documents and by telephone.
Written informed consent was provided by each partici-
pant. The study protocols conformed to the standards set
by the Declaration of Helsinki and were approved by China
Medical University Ethics Committee.
Western blot analysis
Protein was extracted in RIPA lysis buffer and its concen-
tration was determined using a protein assay kit (Bio-Rad,
Hercules, CA, USA). The denatured protein was separated
by 10 % sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (10 % SDS-PAGE) and transferred to a Hybond
membrane. The membranes were blocked overnight in 5 %
skimmed milk in Tris-buffered saline with Tween 20
(TBST, 10 mM Tris-HCl, 150 mM NaCl, 0.1 % Tween 20).
For immunoblotting, the membranes were incubated for
1 h with antibodies against the following proteins: REG4
(RD Systems Inc, Minneapolis, MN, USA); Wnt5a (Santa
Cruz Biotechnology, Dallas, TX, USA); phosphorylated p70
s6k (T421/s424; Cell Signaling, Danvers, MA, USA); Bax
(Santa Cruz Biotechnology); survivin (Santa Cruz Bio-
technology); and VEGF (Santa Cruz Biotechnology). The
membranes were then rinsed with TBST and incubated
with IgG conjugated to horseradish peroxidase (HRP;
Dako, Carpinteria CA, USA) for 1 h. The bands were visu-
alized using a Fuji 4000 imaging system (Fuji, Tokyo,
Japan) after applying electrochemiluminescent (ECL) de-
tection reagents (Santa Cruz Biotechnology). After detec-
tion, the membranes were washed with Western blot (WB)
Stripping Solution (pH2-3, Nacalai, Tokyo, Japan) for
20 min and treated, as described above, using mouse
GAPDH antibody (Sigma-Aldrich St. Louis, MO, USA) as
an internal control.
Real-time reverse transcriptase-polymerase chain reaction
(real-time RT-PCR)
Total RNA was extracted from the cell lines using
QIAGEN RNeasy mini kit (QIAGEN) according to the
manufacturer’s protocol; then 2 μg of total RNA was used
to synthesize cDNA using AMV reverse transcriptase and
random primer (Takara, Ostu, Japan) and then subjected to
real-time PCR examination using the SYBR Premix Ex
Taq™ II kit (Takara) according to the manufacturer’s proto-
col. The oligonucleotide primers for RT-PCR were synthe-
sized by Takara and are listed in Additional file 1: Table S4.
Immunohistochemistry (IHC)
Tissue samples were deparaffinized with xylene, rehy-
drated with alcohol, and subjected to antigen retrieval in
target retrieval solution (TRS; Dako) for 15 min by
microwave oven irradiation (Oriental Rotor Ltd. Co.,
Tokyo, Japan). Non-specific binding was prevented in
5 % bovine serum albumin (BSA) for 5 min. The
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antibody (1:50) or rabbit-anti-(human) Ki-67 antibody
(1:50; Dako) for 15 min and then treated with anti-goat
or anti-rabbit conjugated to HRP (1:100; Dako) for
15 min. After each treatment, the slides were washed
three times with TBST for 1 min, and the proteins were
visualized with 3, 3′-diaminobenzidine (DAB). All incu-
bations were performed in a microwave oven, to allow
intermittent irradiation, as previously described [16].
After counterstained with Mayer’s hematoxylin, the sec-
tions were dehydrated, cleared and mounted. Negative
controls were prepared by omitting the primary
antibody.
One hundred cells were randomly selected and counted
from five representative fields of each section by three in-
dependent observers (CS, YZ, and ZHC). Any inconsis-
tencies were checked by three observers until a final
agreement was reached. Positive expression was graded as
follows: 0 = negative; 1 = 1–49 %; 2 = 50–74 %; 3 ≥ 75 %.
The staining intensity score was graded as follows:
1 = weak; 2 = intermediate; 3 = strong. The grade and score
for REG4 or Ki-67 were multiplied to obtain a final expres-
sion score as follows: − = 0; + = 1–2; ++ = 3–4; +++= 6–9.
Measurement of cancer antigen 125 (CA-125)
Quantitative Chemiluminescence Immunoassay kits
(Gentaur, Paris, France) were used to detect serum
CA-125. Briefly, 50 μl of standard (0–1000 U/mL) speci-
men or control samples were dispensed into appropriate
wells in a microtiter plate. Enzyme conjugate reagent
(100 μL) was added to each well and gently mixed, and
the plate was incubated for 60 min at room temperature.
The wells were rinsed and flicked with wash buffer and
residual water droplets were removed by striking the
well sharply onto absorbent paper. Finally, chemilumin-
escence substrate solution (100 μL) was added to each
well, mixed gently and the absorbance was measured.
Statistical analysis
Statistical analysis was performed using SPSS v. 10.0
software. Spearman’s rank correlation coefficient was
used to analyze rank data, and Mann-Whitney U-test
was used to differentiate the means between different
groups. Kaplan-Meier survival plots were generated and
comparisons between survival curves were made using
Log-rank statistics. Multivariate analysis of parameters
such as age, pathological classification, FIGO staging,
differentiation and Ki-67 expression was carried out
using Cox’s proportional hazard model. A P-value <0.05
was considered to indicate statistical significance.
Results
REG4 mRNA was found to be expressed at a high level
in CAOV3, SKOV3/DDP, HO8910, HO8910-PM celllines compared with those in ES-2, SKOV3 and
OVCAR3 cell lines (Fig. 1a). REG4 protein was
expressed at a high level in CAOV3, HO8910 and
HO8910-PM cells compared with those in the other cell
lines (Fig. 1b). In addition, after treatment with recom-
binant protein REG4 (50 nM), SKOV3 cell growth was
significantly increased (Fig. 1c), compared with that of
normal SKOV3 cells (CTR). To elucidate the role of
REG4 in ovarian cancer, SKOV3 cells were transfected
with a REG4-expressing plasmid and analyzed by real-
time RT-PCR (Fig. 1d) and Western blotting (Fig. 1e).
Subsequent assays compared the treated SKOV3 cells to
control or mock cells (cells transfected with pCI-REG4-
Mut plasmid) and showed significant increases in cell
growth (proliferation assay; P < 0.05; Fig. 1f ); G2/S pro-
gression (flow cytometric cell cycle analysis; P < 0.05;
Fig. 2a); and apoptosis-inhibition (flow cytometric
apoptosis assay; P < 0.05; Fig. 2b). Furthermore, there
was an increase in migration (wound healing assay;
Fig. 3a) and invasion (Transwell cell migration assay;
Fig. 3b). Real-time RT-PCR and Western blotting also
showed increased expression of Wnt5a, p70s6k, survi-
vin and VEGF, in REG4- transfectants or cells treated
with recombinant protein compared to control and
mock cells, while the converse was observed for Bax
expression (Fig. 3c and d).
As determined by real-time RT-PCR, REG4 mRNA
levels were higher in benign ovarian tumors than those in
normal ovarian tissue (P < 0.001; Fig. 4a); and higher in
primary carcinoma than in normal ovarian tissue
(P = 0.048; Fig. 4a). Expression of REG4 mRNA was also
higher in mucinous benign tumors than serous benign
tumors (P = 0.03; Fig. 4b), and in mucinous carcinoma
than serous carcinoma (P < 0.001; Fig. 4b), and in well-
and moderately-differentiated compared to poorly-
differentiated carcinomas (P = 0.011; Fig. 4c); however,
there was no correlation between REG4 mRNA
expression and FIGO staging (R^2 = 0.022, P = 0.225;
Fig. 4d), and between REG4 mRNA expression and age
(P = 0.06; Additional file 1: Table S2).
Immunostaining revealed that REG4 was strongly
expressed in the cytoplasm of serous and mucinous
adenoma, serous and mucinous borderline tumors,
serous and mucinous adenocarcinoma, and adenocar-
cinoma in the omentum; but was not expressed in the
fiber cells of normal ovarian tissue and only very weakly
in the fallopian tube (Fig. 5). As shown in Table 1, REG4
protein expression was detectable in normal ovarian
tissue (23.1 %, 6/26), benign ovarian tumors (70 %, 7/10),
borderline ovarian tumors (81.8 %, 18/22), primary cancer
(50.6 %, 119/235) and metastatic carcinoma in the omen-
tum (61.4 %, 27/44). REG4 expression was significantly
higher in benign tumors, borderline tumors and primary
cancer than that in normal ovarian tissue (P < 0.05; Table 1),
Fig. 1 The effects of REG4 overexpression and the recombinant protein on ovarian cancer cells. Expression levels of REG4 mRNA and protein in
ovarian cancer cell lines (CAOV3, ES-2, HO8910, HO8910-PM, OVCAR3, SKOV3 and SKOV3/DDP) were screened by (a, n = 3) real-time RT-PCR and
(b, respectively) Western blotting. After treatment with the recombinant protein (50 nM), growth of SKOV3 cells was significantly increased
(c, n = 3), and ectopic REG4 overexpression in SKOV3 cells was observed by (d, n = 3) real-time RT-PCR and (e, respectively) Western blotting. The
treatment with the REG4-expressing plasmid or the recombinant protein enhances (f, n = 3) cell proliferation, compared with mock or control
cells. Results are expressed as mean ± SD of three separate experiments; *P < 0.05
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primary and metastatic cancers in the omentum
(P = 0.076; Table 1). In addition, mucinous carcinomas
showed higher REG4 expression than serous ones
(P < 0.05; Table 2). REG4 expression was significantly
higher in well- and moderately- differentiated tumorsthan in poorly-differentiated ones (P = 0.009), and in
patients aged ≥ 56 years than in those aged < 56 years
(P = 0.03), although there were no significant correlation
with FIGO staging or expression of the proliferation
marker, Ki-67 (P > 0.05). In addition, Spearman’s rank
correlation coefficient showed no correlation between
Fig. 2 Effects of REG4 on the cell cycle and cell apoptosis of ovarian cancer cells. The treatment with the REG4-expressing plasmid or its recombinant
protein enhances (a, n = 3) G2/S progression, (b, n = 3) but suppresses apoptosis, compared with control or mock cells. Results are expressed as mean
± SD of three separate experiments; *P < 0.05
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Fig. 3 Effects of REG4 on the invasive and metastatic ability of ovarian cancer cells. The treatment with the REG4-expressing plasmid or the
recombinant protein induces migration in wound healing assays (a, n = 3), and invasion in Matrigel transwell assays (b, n = 3) compared with the
control and mock cells. In addition, expression of Wnt5a, p70s6k, survivin and VEGF is increased at both mRNA and protein levels in SKOV3, as observed
by (c) real-time RT-PCR and (d) Western blotting, respectively; however, Bax expression was decreased. Results are expressed as mean ± SD of three sep-
arate experiments; *P < 0.05
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(r = 0.0061; P = 0.355; Additional file 1: Table S3).
Follow-up information was available for 90 patients
with ovarian cancer for periods ranging (8 lost to follow-up)from 1–103 months (median, 48 months). Survival
curves for the patients with ovarian cancer were strati-
fied according to REG4 protein expression, based on
the IHC results (Fig. 6d & e) and subsequent univariate
Fig. 4 Relationship between REG4 mRNA expression and clinicopathological features of ovarian cancer. REG4 mRNA expression was quantified by
real-time RT-PCR in normal ovarian tissue (No; n = 17), benign (Be; n = 10) and borderline (Bo; n= 6) tumors, primary (Ca; n = 66) and metastatic cancers
in the omentum (Om; n = 21). a REG4 mRNA expression levels are significantly higher in both benign ovarian tumors and primary carcinoma com-
pared to normal ovarian tissue. b Mucinous (Mu) tumors show higher REG4 mRNA expression levels than serous (Se) tumors; and Mann-Whitney
U test showed that REG4 mRNA expression is higher in well- and moderately-differentiated tumors than in poorly-differentiated tumors (c), but there
was no significant difference between (d) FIGO staging I–II & III–IV; *P < 0.05
Fig. 5 Immunohistochemistry of REG4 protein expression in ovarian carcinogenesis. The micrographs show that REG4 protein is not expressed in
the cytoplasm of fiber cells of normal ovary tissue (a) and only weakly in the cytoplasm of fallopian tube cells (b), but it is strongly expressed in the
cytoplasm of serous and mucinous adenoma (c, d); serous and mucinous borderline tumor (e, f); serous (g, h) and mucinous (i, j) adenocarcinoma; and
adenocarcinoma in the omentum (k, l)
Chen et al. BMC Cancer  (2015) 15:471 Page 8 of 12
Table 1 REG4 protein expression during ovarian epithelial
carcinogenesis
Groups n REG4 protein expression
− + ++ +++ PR (%)
Normal ovarian tissue 26 20 2 2 2 23.1*
Benign ovarian tumor 10 3 2 1 4 70.0
Borderline ovarian tumor 22 4 2 2 14 81.8**
Ovarian cancer 235 116 45 41 33 50.6
Metastatic cancer in omentum 44 17 9 12 6 61.4
Groups n REG4 protein expression
− + ++ +++ PR (%)
Primary ovarian cancer 34 7 9 10 8 79.4#
Metastatic cancer in omentum 34 12 9 10 3 64.7
PR, positive rate
*P < 0.05 (normal ovarian tissue compared with benign tumor and
primary carcinoma)
**P < 0.01 (ovarian borderline tumor compared with normal ovarian tissue)
#P = 0.076 (metastatic lesions compared with relative primary cancer tissues)
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relationship between REG4 expression and cumulative
(P = 0.038) or relapse-free survival rate (P = 0.033). Multi-
variate analysis using Cox’s proportional hazard model in-
dicated that FIGO staging (P = 0.038), differentiation (P =
0.007) and REG4 expression (P = 0.006) were independentTable 2 Relationship between REG4 protein expression and clinicop
Clinicopathological features n REG4 protein expr
− +
Age (years)
<56 115 63 25
≥56 120 53 20
Pathological classification
Mucinous adenocarcinoma 26 7 6
Serous adenocarcinoma 174 93 29
Miscellaneous subtypes 35 16 10
FIGO staging
I–II 87 47 15
III–IV 148 69 30
Differentiation
Well-differentiated 59 21 15
Moderately-differentiated 89 39 17
Poorly-differentiated 87 56 13
Ki-67 expression
− 56 32 10
+ 34 13 7
++ 34 18 6
+++ 33 16 7
*P < 0.05, which were pointed out by bold text, indicate statistically significant
**P < 0.01 (Mucinous adenocarcinoma compared with other pathological subtypes)
***P = 0.001 (Well- and moderately-differentiated compared with poorly-differentiatprognostic factors for overall survival of the patients
with ovarian cancer (Table 3); whereas patient age,
remnant foci size, pathological classification or serum
CA-125 levels were not (P > 0.05; Table 3). Of all these
parameters, only REG4 expression was found to be an
independent prognostic factor of relapse-free survival of
the patients with ovarian cancer (P = 0.013), while pa-
tient age, pathological classification, degree of differen-
tiation, remnant foci size, serum CA-125 level and
FIGO staging were not (P > 0.05, Table 3).Discussion
Previous reports have shown that REG4 mRNA is strongly
expressed in inflamed epithelium, dysplasia and cancerous
lesions of ulcerative colitis [17], and REG4 overexpression
has been observed in gastric, colorectal, pancreatic, hepa-
tocellular and prostate cancers [5, 9–14]. Here, real-time
PCR showed that REG4 mRNA was overexpressed in both
benign ovarian tumors and cancers. Furthermore, im-
munohistochemistry showed that REG4 expression was
increased in benign tumors, borderline tumors and pri-
mary carcinoma compared to normal ovarian tissue. This
was consistent with our previous observations in gastric
[13] and colorectal [14] cancers. Taken together, theseathological features of ovarian cancers
ession





















Fig. 6 The prognostic significance of REG4 protein expression in ovarian cancer. Spearman’s rank correlation test showed significant correlation
between REG4 protein expression in normal ovarian tissues and patient age (r = 0.436, P = 0.026, Fig. 6a), and between ovarian carcinomas and
patient age (r = 0.144, P = 0.027, Fig. 6b). When combined together, REG4 expression was still correlated with patient age (r = 0.0161, P = 0.09, Fig. 6c).
Kaplan-Meier survival curves (d, e) indicate a negative association between REG4 protein expression and cumulative or relapse-free survival rates of
patients with ovarian cancer. REG4 protein expression was based on the IHC results classified as: 0 (negative), 1 (+), 2 (++), and 3 (+++)
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sential role as an early event in ovarian carcinogenesis.
We found that REG4 mRNA and protein expression
levels in ovarian cancer were significantly higher in
mucinous tumors than in serous tumors, and were
positively associated with differentiation. Again, this is
consistent with our previous findings in gastric cancer,
which showed positive REG4 expression in signet ring
cells, and mucinous carcinoma, and higher expression
in well- and moderately-differentiated adenocarcinomaTable 3 Multivariate analysis of clinicopathological parameters with
Clinicopathological parameters Cumulative survival
Relative risk (95 % CI)
Age (≥56 years) 1.926 (0.916–4.050)
Pathological subtypes (serous carcinoma) 0.854 (0.329–2.221)
FIGO staging (III–IV) 2.762 (1.058–7.214)
Differentiation degree (poor) 3.007 (1.350–6.700)
REG4 expression (+ to +++) 3.057 (1.369–6.827)
Remnant foci size (≥1 cm) 2.343 (0.995–5.519)
Serum CA-125 level (≥500) 0.813 (0.402–1.645)
Abbreviation: CI = confidence interval
P < 0.05, which were pointed out by bold text, indicate statistically significantthan poorly-differentiated adenocarcinoma [13]. In
addition, REG4 mRNA expression was higher in
mucinous benign tumors and carcinomas compared to
relative serous subtypes, while there was no significant dif-
ference in REG4 mRNA expression between mucinous
benign tumors and mucinous carcinomas, and between
serous benign tumors and serous carcinomas. Huang et al.
reported that REG4 expression was also overexpressed in
mucinous borderline tumors and primary mucinous car-
cinomas [18]. Taken together, these results suggest thatthe overall survival of patients with ovarian cancer
Relapse-free survival
P-value Relative risk (95 % CI) P-value
0.084 1.784 (0.963–3.306) 0.066
0.747 0.731 (0.329–1.625) 0.442
0.038 1.619 (0.745–3.520) 0.224
0.007 1.892 (0.988–3.622) 0.054
0.006 2.282 (1.189–4.380) 0.013
0.051 1.834 (0.869–3.872) 0.112
0.564 1.004 (0.556–1.812) 0.989
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esis of ovarian mucinous carcinoma and differentiation
of ovarian cancer. Furthermore, our observations re-
vealed no significant difference in REG4 mRNA or pro-
tein expression between stages I–II and III–IV ovarian
cancer, which was also consistent with our previous
findings in gastric cancer [13]. Conversely, primary
prostate cancers (PCa) have been reported to express
low levels of REG4 mRNA, whereas the majority of
metastatic PCa tumors expressed high levels [19], and
REG4 expression has been associated with lymph node
metastasis, recurrence of liver metastasis and tumor
stage in colorectal carcinoma [7, 20]. REG4 mRNA
expression levels in surgically resected specimens and
the peritoneal wash were closely related to those in
wall-penetrating gastric carcinoma.
Recently, secretory REG4 protein was found to act as
a potent activator of the EGFR/Akt/AP-1 signaling path-
way, through phosphorylation of EGFR [9, 21]. To eluci-
date the role and molecular mechanisms of REG4 in
ovarian cancer cells, SKOV3 cells were transfected with
REG4-expressing plasmids or exposed to recombinant
REG4. We found that G2/S progression, apoptotic
inhibition, proliferation, migration and invasion were
significantly increased. Further investigation showed that
both treatments increased expression of Wnt5a, p70s6k,
survivin and VEGF at both the mRNA and proteins
levels, but Bax expression was decreased. Wnt5a,
p70s6k, survivin, VEGF and Bax are involved in the
EGFR signaling pathway, apoptosis, invasion and
metastasis in malignancies. Therefore, these findings sug-
gest that increased REG4 protein expression, or its ectopic
overexpression, promotes aggressive behaviors in ovarian
cancer cells by modulating expression of phenotype-
related genes [22–26]. Our results are supported by re-
ports pf previous in vitro and in vivo experiments showing
that REG4 inhibits apoptosis by increasing the expression
of Bcl-2, Bcl-xl and survivin [9, 10].
Although REG4 has been reported to be significantly
correlated with aggressive biological behaviors of malig-
nancies [7, 20], the prognostic relevance of REG4 ex-
pression remains controversial. Both previous reports
found no relationship between REG4 expression and
survival of patients with gastric cancer [13, 24]. In con-
trast, Ohara et al. [20] revealed that REG4 expression was
significantly associated with longer relapse-free survival of
PCa patients and acted as an independent prognostic
factor in PCa. In accordance with previous reports on
gliomas [15] and CRC [7], we found an inverse relation-
ship between REG4 expression and cumulative or relapse-
free survival rate of patients with ovarian cancer. Our
multivariate model indicates that REG4 expression, FIGO
staging and differentiation are independent prognostic fac-
tors of overall survival in the patients with ovarian cancer.REG4 expression was also shown to be an independent
prognostic factor of relapse-free survival.
Conclusions
REG4 expression was upregulated in precancerous ovar-
ian lesions, then marginally downregulated as the ovar-
ian epithelial cells underwent malignant transformation.
Overexpression of REG4 protein increased the aggres-
siveness of ovarian cancer, as indicated by reduced apop-
tosis and increased proliferation, migration and invasion.
We speculate that this may be correlated with the al-
tered expression of Wnt5a, p70s6k, survivin, VEGF and
Bax. Furthermore, REG4 expression was closely linked
with mucinous tumors, differentiation and adverse prog-
nosis of ovarian cancer. Taken together, our findings
suggest that REG4 represents an independent indicator
of poor prognosis in ovarian cancer.
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